脂蛋白(a)功能改变对糖尿病视网膜病变血管生成的影响
本研究探讨2型糖尿病伴或不伴糖尿病视网膜病变患者及健康对照的脂蛋白(a)对视网膜内皮细胞炎症、血管生成及髓系来源促血管生成细胞分化的影响。发现糖尿病视网膜病变患者的脂蛋白(a)丧失抗炎能力、促进血管生成增强,且对促血管生成细胞分化的影响减弱,这些功能差异与脂质组成改变相关。
要点
- 糖尿病视网膜病变患者的脂蛋白(a)不能阻断TNF-α诱导的视网膜内皮细胞VCAM-1/ICAM-1表达,而健康对照的脂蛋白(a)可以。
- 糖尿病视网膜病变患者的脂蛋白(a)促进视网膜内皮细胞血管生成的程度高于健康对照的脂蛋白(a)。
- 健康对照的脂蛋白(a)降低促血管生成细胞CD16和CD105表达,而2型糖尿病患者的脂蛋白(a)无此作用。
核心结论
- 糖尿病视网膜病变患者的脂蛋白(a)不显示健康对照脂蛋白(a)所具有的抗炎能力,但增加视网膜内皮细胞血管生成,且对促血管生成细胞分化的影响小于健康对照脂蛋白(a)。
- 2型糖尿病相关视网膜病变中脂蛋白(a)的这些功能差异与相比健康状态的脂质组成改变相关。
研究设计与样本
- 研究将来自2型糖尿病伴或不伴糖尿病视网膜病变患者及健康对照的脂蛋白(a)/低密度脂蛋白加入TNF-α激活的视网膜内皮细胞。
- 用流式细胞术检测VCAM-1/ICAM-1表达,在促血管生成生长因子刺激的视网膜内皮细胞-周细胞共培养中测定血管生成。
- 通过检测促血管生成细胞标志物表达测定外周血单核细胞的促血管生成细胞分化,并用详细脂质组学分析定量脂蛋白脂质组成。
主要发现
- 糖尿病视网膜病变患者的脂蛋白(a)未能阻断TNF-α诱导的视网膜内皮细胞VCAM-1/ICAM-1表达,而健康对照的脂蛋白(a)可以阻断。
- 糖尿病视网膜病变患者的脂蛋白(a)增加视网膜内皮细胞血管生成的程度高于健康对照的脂蛋白(a)。
- 无糖尿病视网膜病变患者的脂蛋白(a)显示中间特征。
- 健康对照的脂蛋白(a)降低促血管生成细胞中CD16和CD105的表达,而2型糖尿病患者的脂蛋白(a)未降低。
- 2型糖尿病患者的脂蛋白(a)中磷脂酰乙醇胺含量低于健康对照的脂蛋白(a)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetic retinopathy (DR) is a complication of type 2 diabetes mellitus (T2DM). Lipoprotein(a) (Lp(a)) contributes to the progression of DR, but how is unclear. In homeostasis of the retinal microvasculature, myeloid-derived pro-angiogenic cells (PACs) also play a pivotal role, and fail to function properly in diabetic conditions. Here, we explored the putative contribution of Lp(a) from patients with T2DM with/without DR and healthy controls on inflammation and angiogenesis of retinal endothelial cells (RECs), and on PAC differentiation. Subsequently, we compared the lipid composition of Lp(a) from patients to that from healthy controls. METHODS: Lp(a)/LDL obtained from patients and healthy controls were added to TNF-alpha-activated RECs. Expression of VCAM-1/ICAM-1 was measured using flowcytometry. Angiogenesis was determined in REC-pericyte co-cultures stimulated by pro-angiogenic growth factors. PAC differentiation from peripheral blood mononuclear cells was determined by measuring expression of PAC markers. The lipoprotein lipid composition was quantified using detailed lipidomics analysis. RESULTS: Lp(a) from patients with DR (DR-Lp(a)) failed to block TNF-alpha-induced expression of VCAM-1/ICAM-1 in REC whereas Lp(a) from healthy controls (healthy control [HC]-Lp(a)) did. DR-Lp(a) increased REC angiogenesis more than HC-Lp(a) did. Lp(a) from patients without DR showed intermediate profiles. HC-Lp(a) reduced the expression of CD16 and CD105 in PAC, but T2DM-Lp(a) did not. Phosphatidylethanolamine content was lower in T2DM-Lp(a) than in HC-Lp(a). CONCLUSIONS: DR-Lp(a) does not show the anti-inflammatory capacity seen with HC-Lp(a), but increases REC angiogenesis, and affects PAC differentiation less than HC-Lp(a). These functional differences in Lp(a) in T2DM-related retinopathy are associated with alterations in the lipid composition as compared to healthy conditions.
引用
- Shariatzadeh M, Nagtzaam NMA, van Vark-van der Zee L, et al. Altered Functionality of Lipoprotein(a) Impacts on Angiogenesis in Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2023. PMID: 37159194. doi:10.1167/iovs.64.5.8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。